(S)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate | 1354225-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (S)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate
• 英文别名: tert-butyl N-[(2S)-1-(1,3-dioxoisoindol-2-yl)butan-2-yl]carbamate
• CAS: 1354225-74-3
• 化学式: C₁₇H₂₂N₂O₄
• 分子量: 318.373
• InChiKey: KOKKQIRPSMLGST-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate 在 N-甲基吗啉 、 一水合肼 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl (S)-(1-(3,5-diamino-6-chloropyrazine-2-carboxamido)butan-2-yl)carbamate
  参考文献：
  名称：

  Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines

  摘要：

  We report the synthesis and biological evaluation of a series of novel alpha-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 mu g kg(-1) at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.067
• 作为产物：
  描述：

  N-Boc-(S)-(-)-2-氨基-1-丁醇 在 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 (S)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate
  参考文献：
  名称：

  NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

  摘要：

  公开号：

  EP2589592B1

文献信息

• Synthesis of imidacloprid derivatives with a chiral alkylated imidazolidine ring and evaluation of their insecticidal activity and affinity to the nicotinic acetylcholine receptor
  作者：Hisashi Nishiwaki、Mituhiro Kuriyama、Hikaru Nagaoka、Akira Kato、Miki Akamatsu、Satoshi Yamauchi、Yoshihiro Shuto

  DOI：10.1016/j.bmc.2012.09.007

  日期：2012.11

  imidazolidine ring were asymmetrically synthesized to evaluate their insecticidal activity against adult female housefly, Musca domestica, and affinity to the nicotinic acetylcholine receptor of the flies. The bulkier the alkyl group, the lower was the receptor affinity, but the derivatives methylated and ethylated at the R-5-position of the imidazolidine ring were equipotent to the unsubstituted compound. Quantitative

  不对称合成了一系列具有烷基化咪唑烷环的吡虫啉（IMI）衍生物，以评估其对成年雌性家蝇Musca domestica的杀虫活性以及对果蝇的烟碱乙酰胆碱受体的亲和力。烷基越大，受体亲和力越低，但是在咪唑烷环的R -5-位甲基化和乙基化的衍生物与未取代的化合物等价。受体亲和力的定量结构-活性关系（QSAR）分析表明，将取代基引入咪唑烷环基本上是不利的，但在R处引入取代基如果尺寸较小，则允许-5-位置。合成衍生物与受体的结合模型支持QSAR分析，表明在配体结合位点R -5-位置周围的短烷基存在空间。此外，在杀虫活性和受体亲和力之间观察到正相关，这表明即使修饰了咪唑烷环，受体亲和力也是影响杀虫活性的主要因素。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• US8809371B2
  申请人：——

  公开号：US8809371B2

  公开（公告）日：2014-08-19
• US8895585B2
  申请人：——

  公开号：US8895585B2

  公开（公告）日：2014-11-25